drugset / Trial / NCT03164694
APatinib Plus Chemotherapy vErsus Chemotherapy As First-line Treatment for Advanced NSCLC
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to studying the addition of apatinib with chemotherapy to investigate the efficacy and safety of apatinib in combination with chemotherapy in patients with advanced NSCLC.
Timeline
- Start
- 2017-05-20
- Primary completion
- 2025-05-20
- Completion
- 2027-05-20
Outcome
Outcome not reported
Stopped (Enrollment): “No patients enrolled.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rivoceranib | Small molecule | 850 mg | Oral |
| Background | Carboplatin | Small molecule | 5 unknown | — |
| Background | Pemetrexed | Small molecule | 500 mg/m2 | — |